Posted by Michael Wonder on 25 Aug 2023
European Medicines Agency accepts Novaliq’s marketing authorisation application for CyclASol (cyclosporin ophthalmic solution) 0.1% for the treatment of dry eye disease
24 August 2023 - Novaliq today announced that the EMA has accepted the marketing authorisation application for CyclASol (ciclosporin ophthalmic solution) for regulatory review.
CyclASol is an investigational new drug treatment for dry eye disease in patients not responding to tear substitutes.
